Lancet[journal] 检索结果

6341. Trends in population health and demography.

作者: Stuart Gietel-Basten.;Tomas Sobotka.
来源: Lancet. 2021年398卷10300期580-581页

6342. Trends in population health and demography.

作者: Jane N O'Sullivan.
来源: Lancet. 2021年398卷10300期580页

6343. Trends in population health and demography.

作者: Nanna Maaløe.;Natasha Housseine.;Tarek Meguid.;Siri Tellier.;Jos van Roosmalen.;Dan W Meyrowitsch.;Thomas van den Akker.
来源: Lancet. 2021年398卷10300期579-580页

6344. Voriconazole pharmacogenetics.

作者: Nicolas Pallet.;Marie Anne Loriot.
来源: Lancet. 2021年398卷10300期578页

6345. Voriconazole pharmacogenetics - Authors' reply.

作者: Johan A Maertens.;Hetty A Waskin.;Rachel Marceau West.;Peter M Shaw.
来源: Lancet. 2021年398卷10300期578-579页

6346. Min Mehta: surgeon who helped children with scoliosis.

作者: Georgina Ferry.
来源: Lancet. 2021年398卷10300期572页

6347. Chiquita Brooks-LaSure: innovative US federal health director.

作者: Susan Jaffe.
来源: Lancet. 2021年398卷10300期571页

6348. Focusing on island health.

作者: Jacqui Thornton.
来源: Lancet. 2021年398卷10300期569-570页

6349. Lebanese health care racked by medicine shortages.

作者: Saleyha Ahsan.
来源: Lancet. 2021年398卷10300期568页

6350. Haiti's health woes intensify.

作者: Joe Parkin Daniels.
来源: Lancet. 2021年398卷10300期567页

6351. The NHS: the many challenges for leadership.

作者: The Lancet.
来源: Lancet. 2021年398卷10300期559页

6352. A Lebanese physician's dilemma: not how, but with what?

作者: Abdul Rahman Bizri.;Pierre Bou Khalil.
来源: Lancet. 2021年398卷10303期841页

6353. Does vaccine ageism amount to gerontocide?

作者: Peter Lloyd-Sherlock.;Gideon Lasco.;Martin McKee.;Arokiasamy Perianayagam.;Lucas Sempé.
来源: Lancet. 2021年398卷10304期952-953页

6354. Pharmaceutical companies should pay for raiding nature's medicine cabinet.

作者: Adam D Canning.;Russell G Death.;Nathan J Waltham.
来源: Lancet. 2021年398卷10303期840-841页

6355. SARS-CoV-2 vaccination in pregnancy: a unique opportunity for equity.

作者: Erkan Kalafat.;Laura A Magee.;Peter von Dadelszen.;Pat O'Brien.;Asma Khalil.
来源: Lancet. 2021年398卷10304期951页

6356. The costs of PEPFAR's leadership vacuum.

作者: José M Zuniga.;Asia Russell.;Richard Lusimbo.;Sibongile Tshabalala.
来源: Lancet. 2021年398卷10302期741页

6357. Serial intervals in SARS-CoV-2 B.1.617.2 variant cases.

作者: Rachael Pung.;Tze Minn Mak.; .;Adam J Kucharski.;Vernon J Lee.
来源: Lancet. 2021年398卷10303期837-838页

6358. The use of inhaled corticosteroids in early-stage COVID-19.

作者: Dee Mangin.;Michelle Howard.
来源: Lancet. 2021年398卷10303期818-819页

6359. Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study.

作者: Saad Z Usmani.;Alfred L Garfall.;Niels W C J van de Donk.;Hareth Nahi.;Jesus F San-Miguel.;Albert Oriol.;Laura Rosinol.;Ajai Chari.;Manisha Bhutani.;Lionel Karlin.;Lotfi Benboubker.;Lixia Pei.;Raluca Verona.;Suzette Girgis.;Tara Stephenson.;Yusri Elsayed.;Jeffrey Infante.;Jenna D Goldberg.;Arnob Banerjee.;María-Victoria Mateos.;Amrita Krishnan.
来源: Lancet. 2021年398卷10301期665-674页

There is a need for novel therapies for relapsed or refractory multiple myeloma, and B-cell maturation antigen (BCMA) is a validated target. Teclistamab is a bispecific antibody that binds BCMA and CD3 to redirect T cells to multiple myeloma cells. The aim of the MajesTEC-1 study was to evaluate the safety, tolerability, and preliminary efficacy of teclistamab in patients with relapsed or refractory multiple myeloma.

6360. Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial.

作者: Ly-Mee Yu.;Mona Bafadhel.;Jienchi Dorward.;Gail Hayward.;Benjamin R Saville.;Oghenekome Gbinigie.;Oliver Van Hecke.;Emma Ogburn.;Philip H Evans.;Nicholas P B Thomas.;Mahendra G Patel.;Duncan Richards.;Nicholas Berry.;Michelle A Detry.;Christina Saunders.;Mark Fitzgerald.;Victoria Harris.;Milensu Shanyinde.;Simon de Lusignan.;Monique I Andersson.;Peter J Barnes.;Richard E K Russell.;Dan V Nicolau.;Sanjay Ramakrishnan.;F D Richard Hobbs.;Christopher C Butler.; .
来源: Lancet. 2021年398卷10303期843-855页

A previous efficacy trial found benefit from inhaled budesonide for COVID-19 in patients not admitted to hospital, but effectiveness in high-risk individuals is unknown. We aimed to establish whether inhaled budesonide reduces time to recovery and COVID-19-related hospital admissions or deaths among people at high risk of complications in the community.

结果排序

文献格式

出版时间

出版类型

出版语言